Frontlight ResearchEarly access
Taking peoplePhase 3
Prophylactic Anti-aRrhythmic therapy with Amiodarone in critically ill patients admitted for an out-of-hospital Cardiac Arrest with initial shockable rhythm._PARACA
Key facts
- Who runs it
- Centre Hospitalier De Versailles
- Where
- France34 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 674 people, planned
- Started
- 23 Sept 2025
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional
- Record updated
- 27 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patient aged ≥ 18 years
- Admitted in intensive care unit
- Out-of-hospital cardiac arrest with shockable rhythm
- Presumed cardiac or unknown cause
- Delay between ROSC and screening for randomisation < 6 hours
- Informed consent from the patient or a surrogate or deferred consent
- Affiliated to or benefiting from a social insurance
Who cannot take part
- Known limitations in therapy and Do Not Resuscitate-order
- Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)
- History of cardiac conduction disorders, not treated by permanent pacemaker
- Amiodarone allergy
- Refractory ventricular arrhythmia or electrical storm
- Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission
- Patient with known amiodarone long –term treatment
- Patient already included in a clinical trial (other than observational clinical trials)
- Moribund patient due to pre-arrest history (estimated life expectancy < 3 months)
- Pregnant or breastfeeding women
- Indication for amiodarone decided by the physician at ICU admission
- Foreseeable inability to obtain secure venous access for the administration of amiodarone
- Known or suspected hyperthyroidism
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To comparatively determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 27 August 2026